Oncology Medical News about childhood acute lymphoblastic leukemia;dexamthasone-based therapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997â??2004)
The Lancet Oncology - Online First, 09/11/09

Veerman AJ et al. – The results for NHR patients were achieved with high cumulative doses of dexamethasone and vincristine, but without the use of anthracyclines, etoposide, cyclophosphamide, or cranial irradiation, therefore minimising the risk of side-effects.

Methods

From a January 1997 to 1 November 2004, 859 patients with ALL were treated according to the ALL-9 protocol
Patients were stratified into NHR and high risk (HR) groups
HR criteria were white-blood-cell count of ≥ 50 000 cells per ?L, T-cell phenotype, mediastinal mass, CNS or testicular involvement, and Philadelphia chromosome or MLL rearrangement
The NHR group was treated with a three-drug induction (dexamethasone, vincristine, and asparaginase) for 6 weeks, medium-dose methotrexate for 3 weeks, then maintenance therapy
HR patients received a four-drug induction (as for the NHR patients plus daunorubicin) for 6 weeks, high-dose methotrexate for 8 weeks, and two intensification courses before receiving maintenance therapy
No patient received cranial irradiation
Maintenance therapy was given until 109 weeks for all patients and consisted of mercaptopurine and methotrexate for 5 weeks, alternated with dexamethasone and vincristine for 2 weeks

Results

Complete remission was achieved in 592 (98·5%) of the 601 patients in the NHR group and 250 (96·9%) of the 258 in the HR group
Five patients in the NHR group and four in the HR group died during induction
The median f/u for patients alive was 72·2 mos (range, 4·8—132·7 mos)
5-year event-free survival was 81% in all patients: 84% in NHR patients, and 72% in HR patients
Isolated CNS relapses occurred in 22 (2·6%) of 842 patients
DNA index was the strongest predictor of outcome (<1·16 vs ?1·16; relative risk 0·42), followed by age (1—9 vs ?10 years; 2·23) and WBC count (<50 000 vs ?50 000 cells per ?L; 1·60)

<< Previous
Safety of bevacizumab in patients with non-small-cell lung cancer...

Next >>
Amphiregulin and epiregulin mRNA expression in primary tumors...